Title

Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update

Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch

Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update

Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update

Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial